EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting the High-Density Lipoprotein Proteome for the Treatment of Post-Acute Sequelae of SARS-CoV-2

Karsten Grote iD, Ann-Christin Schaefer, Muhidien Soufi, Volker Ruppert, Uwe Linne, Aditya Mukund Bhagwat, Witold Szymanski iD, Johannes Graumann iD, Yana Gercke, Sümeya Aldudak, Denise Hilfiker-Kleiner, Elisabeth Schieffer und 1 weitere

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25084522 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Karsten Grote und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Angiology, and Intensive Care, Philipps University Marburg, 35043 Marburg, Germany. Hauptthemen laut MEDLINE: Proteome, COVID-19, Lipoproteins, HDL, SARS-CoV-2. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Dr. Reinfried Pohl Foundation, German Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Here, we target the high-density lipoprotein (HDL) proteome in a case series of 16 patients with post-COVID-19 symptoms treated with HMG-Co-A reductase inhibitors (statin) plus angiotensin II type 1 receptor blockers (ARBs) for 6 weeks. Patients suffering from persistent symptoms (post-acute sequelae) after serologically confirmed SARS-CoV-2 infection (post-COVID-19 syndrome, PCS, n = 8) or following SARS-CoV-2 vaccination (PVS, n = 8) were included. Asymptomatic subjects with corresponding serological findings served as healthy controls (n = 8/8). HDL was isolated using dextran sulfate precipitation and the HDL proteome of all study participants was analyzed quantitatively by mass spectrometry. Clinical symptoms were assessed using questionnaires before and after therapy. The inflammatory potential of the patients’ HDL proteome was addressed in human endothelial cells. The HDL proteome of patients with PCS and PVS showed no significant differences; however, compared to controls, the HDL from PVS/PCS patients displayed significant alterations involving hemoglobin, cytoskeletal proteins (MYL6, TLN1, PARVB, TPM4, FLNA), and amyloid precursor protein. Gene Ontology Biological Process (GOBP) enrichment analysis identified hemostasis, peptidase, and lipoprotein regulation pathways to be involved. Treatment of PVS/PCS patients with statins plus ARBs improved the patients’ clinical symptoms. After therapy, three proteins were significantly increased (FAM3C, AT6AP2, ADAM10; FDR < 0.05) in the HDL proteome from patients with PVS/PCS. Exposure of human endothelial cells with the HDL proteome from treated PVS/PCS patients revealed reduced inflammatory cytokine and adhesion molecule expression. Thus, HDL proteome analysis from PVS/PCS patients enables a deeper insight into the underlying disease mechanisms, pointing to significant involvement in metabolic and signaling disturbances. Treatment with statins plus ARBs improved clinical symptoms and reduced the inflammatory potential of the HDL proteome. These observations may guide future therapeutic strategies for PVS/PCS patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProteomeCOVID-19Lipoproteins, HDLSARS-CoV-2Hydroxymethylglutaryl-CoA Reductase InhibitorsHumansMaleFemaleMiddle AgedAgedPost-Acute COVID-19 SyndromeAngiotensin II Type 1 Receptor BlockersCOVID-19 Drug TreatmentAdult

Stichwörter der Autor:innen

HDL proteomecase seriescholesterol metabolismdrug therapypost-COVID-19proteomics

Substanzen

ProteomeLipoproteins, HDLHydroxymethylglutaryl-CoA Reductase InhibitorsAngiotensin II Type 1 Receptor Blockers

Autor:innen und Institutionen

  • Department of Cardiology, Angiology, and Intensive Care, Philipps University Marburg, 35043 Marburg, Germany.
  • Mass Spectrometry Facility, Department of Chemistry, Philipps University Marburg, 35043 Marburg, Germany.
  • Institute of Translational Proteomics & Core Facility Translational Proteomics, Philipps University Marburg, 35043 Marburg, Germany.
  • Institute Cardiovascular Complications in Pregnancy and Oncologic Therapies, Philipps University Marburg, 35043 Marburg, Germany.

ORCID-Profile: Karsten Grote, Witold Szymanski, Johannes Graumann, Bernhard Schieffer

Förderung

  • Deutsche Forschungsgemeinschaft
  • Dr. Reinfried Pohl Foundation
  • German Research Foundation
  • institutional funding
  • Open Access Publishing Fund of Philipps-University Marburg

Zitieren

APA

Grote, K., Schaefer, A. C., Soufi, M., Ruppert, V., Linne, U., Mukund Bhagwat, A., Szymanski, W., Graumann, J., Gercke, Y., Aldudak, S., Hilfiker-Kleiner, D., Schieffer, E., & Schieffer, B. (2024). Targeting the High-Density Lipoprotein Proteome for the Treatment of Post-Acute Sequelae of SARS-CoV-2. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25084522

Vancouver

Grote K, Schaefer AC, Soufi M, Ruppert V, Linne U, Mukund Bhagwat A, et al. Targeting the High-Density Lipoprotein Proteome for the Treatment of Post-Acute Sequelae of SARS-CoV-2. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25084522

BibTeX
@article{Grote2024,
  author = {Grote, Karsten and Schaefer, Ann-Christin and Soufi, Muhidien and Ruppert, Volker and Linne, Uwe and Mukund Bhagwat, Aditya and Szymanski, Witold and Graumann, Johannes and Gercke, Yana and Aldudak, Sümeya and Hilfiker-Kleiner, Denise and Schieffer, Elisabeth and Schieffer, Bernhard},
  title = {Targeting the High-Density Lipoprotein Proteome for the Treatment of Post-Acute Sequelae of SARS-CoV-2},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25084522}
}
Kostenlos starten →